Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A1 | P53985 | 19/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.39 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.37 |
| ▸ | SLC16A7 | O60669 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5093405 | 0.84 | SLC16A1 (0.41) | SLC16A1CYP2C9CYP3A4SLC16A3SLC16A7 | |
| SCHEMBL4838695 | 0.78 | SLC16A1 (0.55) | SLC16A1CYP2C9CYP3A4SLC16A3SLC16A7 | |
| SCHEMBL4833502 | 0.75 | SLC16A1 (0.43) | SLC16A1CYP2C9CYP3A4SLC16A3SLC16A7 | |
| SCHEMBL5140584 | 0.74 | SLC16A1 (0.40) | SLC16A1CYP2C9CYP3A4SLC16A3SLC16A7 | |
| SCHEMBL5100191 | 0.74 | SLC16A1 (0.40) | SLC16A1CYP2C9CYP3A4SLC16A3SLC16A7 | |
| SCHEMBL5106150 | 0.73 | SLC16A1 (0.39) | SLC16A1CYP2C9CYP3A4SLC16A3SLC16A7 | |
| SCHEMBL5139602 | 0.73 | SLC16A1 (0.39) | SLC16A1CYP2C9CYP3A4SLC16A3SLC16A7 | |
| SCHEMBL5106237 | 0.73 | SLC16A1 (0.41) | SLC16A1CYP2C9CYP3A4SLC16A3SLC16A7 | |
| SCHEMBL5923797 | 0.72 | SLC16A1 (0.39) | SLC16A1CYP2C9CYP3A4SLC16A3SLC16A7 | |
| SCHEMBL4833249 | 0.71 | SLC16A1 (0.53) | SLC16A1CYP2C9CYP3A4SLC16A3SLC16A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384951-B2 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2008-06-10 | — | — | US | disclosed |
| US-20060052400-A1 | Thienopyriminediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052400-A1 | Thienopyriminediones and their use in the modulation of autoimmune disease | C5, HRH4, CYP2S1 | SLC16A1 4250/4885CYP2C9 113/4885CYP3A4 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.